PROCEPT BioRobotics launches HYDROS robotic system internationally
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
PROCEPT BioRobotics® Announces International Launch of the HYDROS® Robotic System, Expanding Global Access to AI-Enabled Aquablation® Therapy
March 12, 2026 9:00 AM EDTUK marks first international launch of the HYDROS Robotic System, with additional international expansion planned in 2026
SAN JOSE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT), today announced the international expansion of the HYDROS Robotic System, the companys next-generation platform for delivering Aquablation therapy to treat benign prostatic hyperplasia (BPH).
HYDROS is the first AI-enabled robotic platform designed specifically for the treatment of BPH with Aquablation therapy. Leveraging AI-interpreted, real-time ultrasound imaging and advanced image-guided treatment planning, the system enables surgeons to deliver personalized, anatomy-specific therapy with robotic... More
